(6-Ethylpyridin-3-yl)-morpholin-4-ylmethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (6-Ethylpyridin-3-yl)-morpholin-4-ylmethanone
• 英文别名: (6-ethylpyridin-3-yl)-morpholin-4-ylmethanone
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.27
• InChiKey: OSSYCQJEDDVQMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Heterocyclic compounds as kinase inhibitors
  申请人：NUVATION BIO INC.

  公开号：US11174252B2

  公开（公告）日：2021-11-16

  Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为 CDK4 或 CDK6 或其他 CDK 抑制剂的式 (J) 的杂环化合物。这些化合物可用作治疗疾病的药物，尤其可用于肿瘤学。
• HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
  申请人：GIRAFPHARMA LLC

  公开号：US20190248774A1

  公开（公告）日：2019-08-15

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
• UREA DERIVATIVES AS INHIBITORS OF ASK1
  申请人：Hepagene Therapeutics, Inc.

  公开号：US20200339530A1

  公开（公告）日：2020-10-29

  The present technology is directed to compounds, compositions, and methods related to inhibition of ASK1. In particular, the present compounds (e.g., compounds of Formula I as defined herein) and compositions may be used to treat ASK1-mediated disorders and conditions, including, e.g., fibrotic diseases and acute and chronic liver diseases, among others.